Seelos says ALS treatment fails in mid-stage study

Seelos Therapeutics

19/03/2024 12:23

March 19 (Reuters) - Seelos Therapeutics  SEEL.O  said
on Tuesday that its treatment for a neurological disorder called
ALS, or amyotrophic lateral sclerosis, failed to meet the main
goal of a mid-stage trial. 

 (Reporting by Christy Santhosh; Editing by Savio D'Souza)
 ((Christy.Santhosh@thomsonreuters.com;))